Scholarly Index
Marya D. Zilberberg
scPharmaceuticals (United States); 10,243 total citations; 263 total publications; best world rank #118
scPharmaceuticals (United States)
10,243Total citations
263Total publications
53H-index
Published ranking records
| Field | Window | World rank | National rank | Impact score |
|---|---|---|---|---|
| Nosocomial Infections in ICU | Lifetime | 118 | US 47 | 98.81 |
| Pneumonia and Respiratory Infections | Lifetime | 415 | US 172 | 98.52 |
| Clostridium difficile and Clostridium perfringens research | Lifetime | 230 | US 113 | 98.11 |
| Sepsis Diagnosis and Treatment | Lifetime | 384 | US 147 | 98.30 |
| Respiratory Support and Mechanisms | Lifetime | 720 | US 270 | 98.20 |
| Antibiotic Use and Resistance | Lifetime | 297 | US 106 | 98.07 |
| Microscopic Colitis | Lifetime | 482 | US 141 | 97.56 |
| Emergency and Acute Care Studies | Lifetime | 743 | US 414 | 96.50 |
| Bacterial Identification and Susceptibility Testing | Lifetime | 679 | US 284 | 96.66 |
| Urinary Tract Infections Management | Lifetime | 714 | US 336 | 95.98 |
| Pneumonia and Respiratory Infections | 2021-2025 | 525 | US 148 | 91.14 |
| Nosocomial Infections in ICU | 2021-2025 | 194 | US 35 | 88.32 |
| Antibiotic Use and Resistance | 2021-2025 | 690 | US 157 | 88.45 |
| Urinary Tract Infections Management | 2021-2025 | 493 | US 157 | 84.26 |